Acuitas

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas’s clinically validated LNP technology has enabled two approved products, as well as 33 clinical trials in the last three years, including: - COMIRNATY® for Covid-19 by Pfizer-BioNTech, - ONPATTRO® for transthyretin amyloidosis by Alnylam Pharmaceuticals, - First in-human proof of concept for genome base editing, and - First personalized CRISPR therapy.

Today, Acuitas is advancing next-generation LNP to support a variety of modalities. These therapies include targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent infectious disease vaccines, as well as oncology vaccines, including personalized cancer vaccines.